United Therapeutics Corp. Stock Price, News & Analysis

United Therapeutics Corporation (Nasdaq: UTHR) will report its first quarter 2023 financial results on May 3, 2023, before the market opens. A public webcast will follow at 9:00 a.m. Eastern Time, accessible via the company's website. As a public benefit corporation, United Therapeutics is committed to addressing unmet medical needs and enhancing the availability of transplantable organs through innovative pharmaceutical therapies. The company emphasizes its mission-driven approach, aiming to benefit both patients and stakeholders.

Forward-looking statements regarding their future innovations highlight potential risks and uncertainties that may affect actual results. For detailed information, interested parties can refer to their filings with the Securities and Exchange Commission.

United Therapeutics (NASDAQ: UTHR) has announced that it will present research from its development portfolio at two significant medical conferences: the ISHLT 43rd Annual Meeting and ATS International Conference, both scheduled for April and May 2023, respectively. Key presentations will include findings from the phase 4 ARTISAN study aimed at treating pulmonary arterial hypertension through enhanced treprostinil administration and results from the EXPEDITE study highlighting the positive effects of Remodulin induction prior to Orenitram therapy. The data presented will focus on improving patient outcomes, emphasizing geographical disparities in PAH care, and showcasing the company's innovative xenotransplantation research.

United Therapeutics Corporation (Nasdaq: UTHR) announced that Dr. Martine Rothblatt, CEO and Chairperson, will present an update on the company's business during a fireside chat at the Oppenheimer 33rd Annual Healthcare Conference. The session is scheduled for March 13, 2023, from 11:20 a.m. to 11:50 a.m., EDT, and will be accessible via a live webcast on the company's website. An archived version will be available for 90 days post-event. United Therapeutics is dedicated to addressing unmet medical needs through innovative therapies and technologies, being the first biotech firm to operate as a public benefit corporation.

United Therapeutics Corporation (Nasdaq: UTHR) announced that President and COO Michael Benkowitz will provide a business overview at the Cowen 43rd Annual Health Care Conference in Boston on March 7, 2023, from 9:10 a.m. to 9:40 a.m. EST. The session will be accessible via a live webcast on the company's website and an archived version will be available for 90 days post-event. United Therapeutics, as a public benefit corporation, focuses on innovative pharmaceutical therapies and technologies for transplantable organs, aiming to meet the medical needs of patients.

United Therapeutics Corporation (Nasdaq: UTHR) reported a record revenue of $1.94 billion for the year ending December 31, 2022, marking an 18% increase from 2021. The fourth quarter revenues reached $491.5 million, an 18% rise year-over-year. Key products, especially Tyvaso, saw significant growth, with sales increasing 46% in Q4 and 44% for the full year. The company aims to double its revenue to a $4 billion run rate by 2025, driven by ongoing patient growth and pivotal clinical data expected for Tyvaso and ralinepag.